# L&C Bio L&C Bio is a Corporate Investor based in Seongnam-si, South Korea. ## Overview - **Organization type:** Corporate Investor - **Headquarters:** Seongnam-si, South Korea - **Region:** Asia - **Address:** Units 605–607, 474, Dunchon-daero, Suntech City, Sangdaewon-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do, South Korea - **Founded:** 2011 - **Assets under management:** $150M – $200M (Altss estimate) - **Website:** lncbio.co.kr ## Regulatory record - **Reports private funds:** No ## About L&C Bio was established in 2011 by CEO Lee Hwan-chul in Seongnam, South Korea, as an operating company that would generate its own investment capital through commercial tissue banking, medical device sales, and pharmaceutical manufacturing. The firm processes human tissue for transplant and surgical repair while developing a portfolio of regenerative medicine products, creating an unusual structure where an industrial operator also functions as a corporate venture investor. Its revenue base spans prescription medicine, over-the-counter drugs, and cosmetic products distributed across domestic Korean markets and through strategic partnerships in China. The firm invests across the full venture spectrum — from seed and early-stage biotechnology startups to expansion-stage and growth-equity rounds — using its own balance sheet rather than third-party limited-partner commitments. Confirmed portfolio targets include developers of regenerative therapeutics, tissue-engineering platforms, and adjacent medical-device technologies where L&C Bio's own manufacturing infrastructure can accelerate commercialization. The investment operation is lean and closely held, with Lee maintaining control as the largest shareholder and primary decision-maker for both the operating business and the allocation function. Real-estate assets tied to the operating company include a human-tissue processing headquarters in Seongnam, an R&D center and separate sales-and-marketing office in Seoul's Seocho district, a pharmaceutical plant in Anseong, and a manufacturing facility in Kunshan, Jiangsu Province, China — giving the firm a physical-network density unusual for an entity of its estimated asset base. L&C Bio also maintains a corporate labor welfare fund as an internal philanthropic vehicle. An additional operational subsidiary, L&C ES, operates from Busan. In addition to its commercial footprint, the firm holds accredited-member status with the Association for Advancing Tissue and Biologics (AATB), a credential that imposes processing and storage standards on its tissue-banking operations. The structural differentiator is the tight coupling of a regulatory-intensive operating business with a discretionary venture-investment arm — a configuration that forces any prospective portfolio company to pass not only an investment-return threshold but also a commercial-relevance screen tied to L&C Bio's own product lines and distribution channels. This dual identity makes the firm a strategic co-investor for life-science GPs targeting the Korean and Chinese markets, and limits competition with purely financial venture funds. ## Sectors - Healthcare Services - Regenerative Medicine - Biotechnology ## Offices - Seoul, South Korea - Kunshan, Jiangsu Province, China - Anseong-si, Gyeonggi-do, South Korea - Busan, South Korea ## People - Lee Hwan-chul — Chief Executive Officer ## Questions ### Who runs investment decisions at L&C Bio? Founder and CEO Lee Hwan-chul controls both the operating company and the investment allocation function. The firm does not maintain a separate investment committee or external advisory board — capital deployment decisions originate with Lee and his senior management team, making the investment function essentially a single-decision-maker corporate venture arm integrated into the manufacturing business. ### How does L&C Bio's corporate venture arm source deals? Deal flow is generated primarily through the firm's position in the tissue-banking and regenerative-medicine supply chain, its AATB accreditation network, and its commercial distribution partnership with Shanghai JR Life in China. Because L&C Bio operates physical manufacturing and processing facilities, potential portfolio companies often enter the pipeline as commercial partners or technology licensors before a venture investment is considered. ### Does L&C Bio participate in fund commitments or only direct deals? L&C Bio's investment program is structured entirely around direct venture investments rather than limited-partner fund commitments. The firm seeks equity positions in companies developing technologies adjacent to its own product lines — regenerative medicine, wound care, and tissue engineering — and prefers transactions where its manufacturing infrastructure can serve as a commercialization accelerant for the portfolio company. ### What investment stages does L&C Bio target? The firm invests from seed rounds through growth and expansion-stage transactions, with a willingness to hold positions into the later-stage private rounds of companies that align with its commercial strategy. Its Chinese market access through the Shanghai JR Life partnership makes it an active participant in cross-border rounds for life-science companies expanding into Northeast Asia. ### How is L&C Bio's investment capital separated from its operating business? There is no formal separation — the venture-investment activity is funded directly from the operating company's balance sheet and managed by the same leadership team that runs the tissue-processing and pharmaceutical divisions. This structure means investment tempo and check size fluctuate with the operating company's free cash flow rather than following a fixed capital-call schedule. ### What is L&C Bio's known regulatory posture as an accredited tissue bank? L&C Bio holds accreditation from the Association for Advancing Tissue and Biologics (AATB), a US-based standards body that imposes processing, storage, and donor-screening requirements on member facilities. This accreditation places the firm's tissue-banking operations under externally audited quality systems, which in turn shapes its investment thesis toward portfolio companies whose technologies can withstand similar regulatory scrutiny. ## Related profiles - [Robins Foundation](https://altss.com/profile/robins-foundation) - [São Sebastião Prev](https://altss.com/profile/s-o-sebasti-o-prev) --- Last updated: 2026-08-11T02:43:31.692Z Canonical page: https://altss.com/profile/l-c-bio Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology